ArKal Medical is developing a novel continuous glucose monitoring system for the management of diabetes. ArKal’s monitoring system is said to be designed to eliminate many of the inconveniences of current glucose monitoring technologies.
Arvind Jina, president and CEO of ArKal Medical, said: “We are extremely pleased to have the support of such a strong group of investors and this latest infusion of capital is a positive endorsement of the company’s team, technology and strategy. With this investment, we will fund the next stage of corporate and product milestones.”